New patent expiration for Foldrx Pharms drug VYNDAQEL
Annual Drug Patent Expirations for VYNDAQEL Vyndaqel is a drug marketed by Foldrx Pharms and is included in one NDA. […]
New patent expiration for Foldrx Pharms drug VYNDAQEL Read Post »
Annual Drug Patent Expirations for VYNDAQEL Vyndaqel is a drug marketed by Foldrx Pharms and is included in one NDA. […]
New patent expiration for Foldrx Pharms drug VYNDAQEL Read Post »
VENTOLIN HFA (albuterol sulfate) Glaxosmithkline Patent: 7,832,351 Expiration: Dec 19, 2023 See More … For more information on how DrugPatentWatch
Drug Patent Expirations for the Week of December 17, 2023 Read Post »
VENTOLIN HFA (albuterol sulfate) Glaxosmithkline Patent: 7,832,351 Expiration: Dec 19, 2023 See More … For more information on how DrugPatentWatch
Drug Patent Expirations for the Week of December 17, 2023 Read Post »
Annual Drug Patent Expirations for RAPIVAB Rapivab is a drug marketed by Biocryst and is included in one NDA. It
Annual Drug Patent Expirations for PRADAXA Pradaxa is a drug marketed by Boehringer Ingelheim and is included in two NDAs.
New patent expiration for Boehringer Ingelheim drug PRADAXA Read Post »
Annual Drug Patent Expirations for DYMISTA Dymista is a drug marketed by Mylan Speciality Lp and is included in one
New patent expiration for Mylan Speciality drug DYMISTA Read Post »
Annual Drug Patent Expirations for THALOMID Thalomid is a drug marketed by Bristol-myers and is included in one NDA. It
New patent expiration for Bristol-myers drug THALOMID Read Post »
Annual Drug Patent Expirations for OTEZLA Otezla is a drug marketed by Amgen Inc and is included in one NDA.
Annual Drug Patent Expirations for XOPENEX+HFA Xopenex Hfa is a drug marketed by Lupin and is included in one NDA.
New patent expiration for LUPIN drug XOPENEX HFA Read Post »
Get fresh news and insights, drug patent expirations & more…